Southern African Journal of HIV Medicine (Sep 2019)

Emtricitabine-induced pure red cell aplasia

  • Nithendra Manickchund,
  • Camille du Plessis,
  • Melanie-Anne A. John,
  • Thandekile C. Manzini,
  • Bernadett I. Gosnell,
  • Richard J. Lessells,
  • Yunus S. Moosa

DOI
https://doi.org/10.4102/sajhivmed.v20i1.983
Journal volume & issue
Vol. 20, no. 1
pp. e1 – e3

Abstract

Read online

Introduction: Anemia is common in HIV. Parvo B19 infection is a well-recognised cause of red cell aplasia. Other causes of persistent pure red cell aplasia (PRCA) include anti-retroviral drugs such as zidovudine and lamivudine. We describe a case of PRCA that strongly implicates emtricitabine as the probable cause. Patient presentation: Patient was HIV positive and on treatment with a fixed drug combination consisting of tenofovir, emtricitabine and efavirenz for 3 months when she developed severe transfusion dependent anemia. The anemia, attributed to PRCA, was persistent and transfusion dependent for about one year. Management and outcome: Replacement of emtricitabine with abacavir resulted in a prompt, complete and lasting resolution of the anaemia, suggesting an etiologic role of emtricitabine in the PRCA. Conclusion: Emtricitibine is a rare cause of pure red cell aplasia.

Keywords